TALIS BIOMEDICAL CORP (TLIS) Financials
Newest figures come from the 10-Q for Q2 FY2024, filed Aug 19, 2024. Each column of the statement tables below links to the filing it was taken from.
TALIS BIOMEDICAL CORP (TLIS) reported $408K in revenue over the twelve months to Jun 30, 2024, down 85.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Talis remains a development-stage business: shrinking R&D reduced losses, but revenue is falling and operations still consume cash.
The 2023 loss improvement reflects a smaller development budget more than commercial scale: R&D fell from$70.8M in FY2022 to$40.7M . Revenue also fell from$4.8M to$2.1M , so lower costs—not growth—explain the narrower loss.
Cash conversion remains weak: operating cash flow was
Assets contracted from
Financial Health Signals
TALIS BIOMEDICAL CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
TALIS BIOMEDICAL CORP scores -9.30, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.2M) relative to total liabilities ($25.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
TALIS BIOMEDICAL CORP passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
TALIS BIOMEDICAL CORP reported a net loss of $62.0M while operations used $53.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TALIS BIOMEDICAL CORP generated $0 in revenue in Q2 2024. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
TALIS BIOMEDICAL CORP's EBITDA was -$9.5M in Q2 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.5% from the same quarter a year earlier. Against the prior quarter it is up 31.5%.
TALIS BIOMEDICAL CORP reported -$8.8M in net income in Q2 2024. This represents an increase of 41.1% from the same quarter a year earlier. Against the prior quarter it is up 32.1%.
TALIS BIOMEDICAL CORP earned -$4.86 per diluted share (EPS) in Q2 2024. Against the prior quarter it is up 32.0%.
Cash & Balance Sheet
TALIS BIOMEDICAL CORP recorded an outflow of $11.3M in free cash flow in Q2 2024, representing a cash shortfall after capex. This represents an increase of 23.2% from the same quarter a year earlier. Against the prior quarter it is down 76.3%.
TALIS BIOMEDICAL CORP held $59.9M in cash as of Q2 2024; long-term debt is not reported for that period.
Not reported for Q2 2024.
Margins & Returns
TALIS BIOMEDICAL CORP's ROE was -18.2% in Q2 2024, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.8 percentage points.
Not reported for Q2 2024.
Not reported for Q2 2024.
Not reported for Q2 2024.
Capital Allocation
TALIS BIOMEDICAL CORP invested $1.6M in research and development in Q2 2024. This represents a decrease of 84.8% from the same quarter a year earlier. Against the prior quarter it is down 36.8%.
TALIS BIOMEDICAL CORP reported no capital expenditure in Q2 2024. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2024.
TLIS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $73K-94.0% | $195K-24.1% | $140K-82.4% | $581K+1.6% | $1.2M-61.8% | $257K-70.0% | $796K+265.1% |
| Cost of Revenue | $0-100.0% | $6K-70.0% | $8K-99.7% | $6K-99.5% | $7K-99.5% | $20K-99.4% | $2.3M | $1.2M |
| Gross Profit | $0-100.0% | $67K-94.4% | $187K+109.0% | $134K+130.5% | $574K+178.6% | $1.2M+458.7% | -$2.1M-341.8% | -$440K-301.8% |
| R&D Expenses | $1.6M-84.8% | $2.5M-81.6% | $8.0M-47.2% | $8.3M-52.6% | $10.6M-39.2% | $13.8M-33.4% | $15.2M-10.7% | $17.5M-32.2% |
| SG&A Expenses | $8.0M+24.4% | $11.7M+82.1% | $6.6M-38.8% | $8.8M-0.2% | $6.4M-30.2% | $6.4M-46.4% | $10.8M-12.3% | $8.8M-31.0% |
| Operating Income | -$9.6M+41.6% | -$14.1M+25.7% | -$14.5M+48.6% | -$17.0M+36.6% | -$16.4M+39.9% | -$19.0M+42.4% | -$28.1M+1.4% | -$26.8M+30.3% |
| EBITDA | -$9.5M+41.5% | -$13.9M+26.4% | -$14.2M+40.5% | -$16.8M+28.7% | -$16.2M+38.3% | -$18.8M+42.3% | -$23.9M+13.3% | -$23.5M+38.5% |
| Net Income | -$8.8M+41.1% | -$13.0M+26.9% | -$13.5M+50.0% | -$15.7M+39.7% | -$15.0M+44.3% | -$17.8M+46.1% | -$26.9M+6.0% | -$26.0M+32.3% |
| EPS (Basic) | -$4.86+41.2% | -$7.15+27.3% | -$7.39+50.3% | -$8.62+40.3% | -$8.27+44.9% | -$9.84-687.2% | -$14.86-21128.6% | -$14.44-869.1% |
| EPS (Diluted) | -$4.86 | -$7.15+27.3% | -$7.39+50.3% | -$8.62+40.3% | -$8.27 | -$9.84 | -$14.86 | -$14.44 |
| Diluted Shares (Avg) | 2M | 2M+0.5% | N/A | 2M+1.0% | 2M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
TLIS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $72.7M-40.9% | $82.5M-38.0% | $94.7M-44.1% | $107.2M-44.8% | $123.1M-44.5% | $133.1M-42.3% | $169.3M-36.3% | $194.1M-36.0% |
| Current Assets | $63.6M-37.6% | $71.2M-38.4% | $77.7M-41.7% | $89.5M-40.5% | $102.0M-41.4% | $115.6M-42.4% | $133.3M-43.6% | $150.4M-45.8% |
| Cash & Equivalents | $59.9M-39.0% | $70.3M-37.7% | $76.7M-41.1% | $88.0M-38.8% | $98.2M-40.6% | $113.0M-39.8% | $130.2M-44.0% | $143.8M-47.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.0M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $24.1M-10.5% | $25.8M+12.6% | $25.6M-39.9% | $25.7M-38.4% | $26.9M-39.8% | $22.9M-17.5% | $42.6M+33.6% | $41.7M-5.9% |
| Current Liabilities | $8.2M-11.5% | $9.5M-15.3% | $8.8M-30.8% | $8.4M-25.7% | $9.3M-33.4% | $11.2M-26.8% | $12.7M-33.7% | $11.4M-63.7% |
| Non-Current Liabilities | $15.9M-10.0% | $16.3M+39.1% | $16.8M-43.8% | $17.2M-43.2% | $17.6M-42.6% | $11.7M-6.2% | $29.9M+134.4% | $30.3M+134.0% |
| Total Equity | $48.6M-49.4% | $56.7M-48.5% | $69.1M-45.5% | $81.6M-46.5% | $96.2M-45.7% | $110.1M-45.7% | $126.7M-45.8% | $152.4M-41.1% |
| Retained Earnings | -$561.8M-10.0% | -$553.0M-11.5% | -$540.0M-13.0% | -$526.5M-16.7% | -$510.8M-20.2% | -$495.8M-24.6% | -$478.0M-31.0% | -$451.0M-34.1% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
TLIS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.3M+20.6% | -$6.4M+61.0% | -$11.4M+16.1% | -$11.1M+46.5% | -$14.3M+35.2% | -$16.5M+62.4% | -$13.5M+66.8% | -$20.8M+72.1% |
| Depreciation & Amortization | $84K-50.0% | $262K+50.6% | $211K-94.1% | $217K-93.4% | $168K-82.9% | $174K-52.1% | $3.6M+280.1% | $3.3M+1328.6% |
| Stock-Based Compensation | $791K-26.5% | $601K-49.2% | N/A | $1.1M-17.3% | $1.1M-13.6% | $1.2M-23.4% | N/A | $1.3M-47.7% |
| Capital Expenditures | $0-100.0% | $0-100.0% | -$93K+89.8% | $70K-91.9% | $485K+143.7% | $24K-95.3% | $49K-95.0% | $860K+13.3% |
| Free Cash Flow | -$11.3M+23.2% | -$6.4M+61.0% | -$11.4M+15.8% | -$11.2M+48.3% | -$14.8M+33.6% | -$16.5M+62.7% | -$13.6M+67.4% | -$21.7M+71.3% |
| Investing Cash Flow | $84K+117.3% | $30K+225.0% | $93K+289.8% | -$70K+91.9% | -$485K-143.7% | -$24K+95.3% | -$49K+95.0% | -$860K-13.3% |
| Financing Cash Flow | $0 | $2K-93.9% | $0 | $0-100.0% | $0 | $33K-89.5% | $0-100.0% | $92K-90.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TLIS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 91.8%-6.6pp | 95.9% | 95.7%+151.0pp | 98.8% | 98.4%+108.8pp | -807.4% | -55.3%-155.3pp |
| Operating Margin | N/A | -19338.4% | -7413.3% | -12122.1% | -2821.2% | -1559.7% | -10938.9% | -3365.1% |
| Net Margin | N/A | -17856.2% | -6902.6% | -11201.4% | -2587.6% | -1464.0% | -10478.2% | -3269.0% |
| Return on Equity | -18.2%-2.6pp | -23.0%-6.8pp | -19.5%+1.8pp | -19.2%-2.1pp | -15.6%-0.4pp | -16.2%+0.1pp | -21.2%-9.0pp | -17.1%-2.2pp |
| Return on Assets | -12.2%+0.1pp | -15.8%-2.4pp | -14.2%+1.7pp | -14.6%-1.2pp | -12.2%0.0pp | -13.4%+0.9pp | -15.9%-5.1pp | -13.4%-0.7pp |
| Current Ratio | 7.76-3.2x | 7.51-2.8x | 8.86-1.7x | 10.60-2.6x | 11.01-1.5x | 10.34-2.8x | 10.52-1.8x | 13.22+4.4x |
| Debt-to-Equity | 0.50+0.2x | 0.46+0.2x | 0.370.0x | 0.310.0x | 0.280.0x | 0.21+0.1x | 0.34+0.2x | 0.27+0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.000.0x | 0.000.0x |
| FCF Margin | N/A | -8804.1% | -5871.8% | -8010.0% | -2540.3% | -1353.8% | -5288.7% | -2723.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TALIS BIOMEDICAL CORP TLIS | FY2023 | $2.1M | -$62.0M | N/A | $5.2M | — |
| IR-MED INC IRME | FY2024 | N/A | N/A | N/A | $231K | — |
| ODYSSEY HEALTH INC ODYY | FY2025 | N/A | N/A | N/A | $666K | — |
Where TALIS BIOMEDICAL CORP Ranks
Frequently Asked Questions
What is TALIS BIOMEDICAL CORP's annual revenue?
TALIS BIOMEDICAL CORP (TLIS) reported $2.1M in total revenue for fiscal year 2023. This represents a -55.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is TALIS BIOMEDICAL CORP's revenue growing?
TALIS BIOMEDICAL CORP (TLIS) revenue declined by 55.7% year-over-year, from $4.8M to $2.1M in fiscal year 2023.
Is TALIS BIOMEDICAL CORP profitable?
No, TALIS BIOMEDICAL CORP (TLIS) reported a net income of -$62.0M in fiscal year 2023.
What is TALIS BIOMEDICAL CORP's EBITDA?
TALIS BIOMEDICAL CORP (TLIS) had EBITDA of -$66.0M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is TALIS BIOMEDICAL CORP's gross margin?
TALIS BIOMEDICAL CORP (TLIS) had a gross margin of 98.1% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is TALIS BIOMEDICAL CORP's return on equity (ROE)?
TALIS BIOMEDICAL CORP (TLIS) has a return on equity of -89.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What is TALIS BIOMEDICAL CORP's free cash flow?
TALIS BIOMEDICAL CORP (TLIS) recorded an outflow of $53.7M in free cash flow during fiscal year 2023. This represents a 47.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TALIS BIOMEDICAL CORP's operating cash flow?
TALIS BIOMEDICAL CORP (TLIS) recorded an outflow of $53.2M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are TALIS BIOMEDICAL CORP's total assets?
TALIS BIOMEDICAL CORP (TLIS) had $94.7M in total assets as of fiscal year 2023, including both current and long-term assets.
What are TALIS BIOMEDICAL CORP's capital expenditures?
TALIS BIOMEDICAL CORP (TLIS) invested $486K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does TALIS BIOMEDICAL CORP spend on research and development?
TALIS BIOMEDICAL CORP (TLIS) invested $40.7M in research and development during fiscal year 2023.
What is TALIS BIOMEDICAL CORP's current ratio?
TALIS BIOMEDICAL CORP (TLIS) had a current ratio of 8.86 as of fiscal year 2023, which is generally considered healthy.
What is TALIS BIOMEDICAL CORP's debt-to-equity ratio?
TALIS BIOMEDICAL CORP (TLIS) had a debt-to-equity ratio of 0.37 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is TALIS BIOMEDICAL CORP's return on assets (ROA)?
TALIS BIOMEDICAL CORP (TLIS) had a return on assets of -65.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
How does TALIS BIOMEDICAL CORP's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, TALIS BIOMEDICAL CORP (TLIS) held $76.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $53.2M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is TALIS BIOMEDICAL CORP's Altman Z-Score?
TALIS BIOMEDICAL CORP (TLIS) has an Altman Z-Score of -9.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is TALIS BIOMEDICAL CORP's Piotroski F-Score?
TALIS BIOMEDICAL CORP (TLIS) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TALIS BIOMEDICAL CORP's earnings high quality?
TALIS BIOMEDICAL CORP (TLIS) reported a net loss of $62.0M while operations used $53.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.